Evidence map›Paper›PMID 28981100›Full record

ArticleCell death & disease2017

STAT1β enhances STAT1 function by protecting STAT1α from degradation in esophageal squamous cell carcinoma.

Ying Zhang, Yelong Chen, Hailong Yun, Zhaoyong Liu, Min Su, Raymond Lai

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Macrophage Zc3h12c Limits Tissue Inflammation and Injury via Alternative Splicing of Pre-mRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Predicting STAT1 as a prognostic marker in patients with solid cancer.Therapeutic advances in medical oncology · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Ying ZhangDepartment of Pathology, Shantou University Medical College, Shantou, Guangdong Province, China.
Yelong ChenDepartment of Pathology, Shantou University Medical College, Shantou, Guangdong Province, China.
Hailong YunDepartment of Pathology, Shantou University Medical College, Shantou, Guangdong Province, China.
Zhaoyong LiuDepartment of Orthopaedics, First Affiliated Hospital of Shantou University Medical College, 57 Changping Road, Shantou, Guangdong 515041, China.
Min SuDepartment of Pathology, Shantou University Medical College, Shantou, Guangdong Province, China.
Raymond LaiDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Shantou University Medical College · CNFirst Affiliated Hospital of Shantou University Medical College · CNShantou University · CNUniversity of Alberta · CA

Funding

CIHR
6 · The paper itself

Abstract

STAT1, which carries tumor suppressor functions in several models, consists of two isoforms, namely STAT1α and STAT1β. The biological function and significance of STAT1β has never been examined in human cancer. We examined STAT1β function in esophageal squamous cell carcinoma (ESCC) by transfecting a STAT1β gene into various ESCC cell lines. The interaction between STAT1α and STAT1β was examined by using co-immunoprecipitation and confocal microscopy. The prognostic significance of STAT1β expression, detectable by immunohistochemistry and western blot, was evaluated in a large cohort of ESCC patients. Enforced expression of STAT1β induced and prolonged the expression and phosphorylation of STAT1α in ESCC cells, and these effects were amplified by gamma-interferon (IFN-γ). We also found that STAT1β interacts with STAT1α and decreases STAT1α degradation by the proteasome. Moreover, STAT1β substantially increased the DNA binding and transcription activity of STAT1. STAT1β also sensitized ESCC cells to chemotherapeutic agents, including cisplatin and 5-flurouracil. Using western blot and immunohistochemistry, we found that STAT1β was frequently decreased in esophageal cancer, as compared to their adjacent benign esophageal epithelial tissue. Loss of STAT1β significantly correlated with lymph node metastasis, invasion and shorter overall survival in ESCC patients. Therefore, STAT1β plays a key role in enhancing the tumor suppressor function of STAT1α, in ESCC, in a manner that can be amplified by IFN-γ.

Indexed as

AgedApoptosisCarcinoma, Squamous CellCell Line, TumorCisplatinDisease-Free SurvivalEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleGene Expression Regulation, NeoplasticHumansInterferon-gammaInterferon-Stimulated Gene Factor 3Lymphatic MetastasisMaleMiddle AgedCisplatingamma interferon activation factorIFNG protein, humanInterferon-gammaInterferon-Stimulated Gene Factor 3Protein IsoformsSTAT1 protein, humanSTAT1 Transcription Factor

Identifiers

PMID28981100
PMCPMC5682650
OpenAlexW2763811454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.